Publikasi Scopus 926 artikel (Per 14 Maret 2022)

Lee Y.-S., Oh Y.S., Choi E.-K., Chern A.K.C., Jiampo P., Chutinet A., Hanafy D.A., Trivedi P., Zhai D.
57369401600;14021940000;35558194200;57219941181;57219936937;15724336700;55431326800;57219936294;57219941292;
Patient perception and treatment convenience of dabigatran versus vitamin K antagonist when used for stroke prophylaxis in atrial fibrillation: Real-world Evaluation of Long-term Anticoagulant Treatment Experience (RE-LATE) study
2021
Open Heart
8
2
e001745
Department of Internal Medicine, Daegu Catholic University College of Medicine, Daegu, South Korea; Department of Internal Medicine, Catholic University of Korea, Seoul, South Korea; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Department of Cardiology, Columbia Asia Hospital, Taiping, Malaysia; Department of Medicine, Bhumibol Adulyadej Hospital, Bangkok, Thailand; Chulalongkorn Stroke Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Division of Neurology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand; Cardiology and Vascular Medicine, Pusat Jantung Nasional Harapan Kita, Jakarta, Indonesia; Cardiology and Vascular Medicine, University of Indonesia Faculty of Medicine, Jakarta, Indonesia; Boehringer Ingelheim Singapore Pte Ltd, Singapore, Singapore; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, United States
Lee, Y.-S., Department of Internal Medicine, Daegu Catholic University College of Medicine, Daegu, South Korea; Oh, Y.S., Department of Internal Medicine, Catholic University of Korea, Seoul, South Korea; Choi, E.-K., Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Chern, A.K.C., Department of Cardiology, Columbia Asia Hospital, Taiping, Malaysia; Jiampo, P., Department of Medicine, Bhumibol Adulyadej Hospital, Bangkok, Thailand; Chutinet, A., Chulalongkorn Stroke Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand, Division of Neurology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand; Hanafy, D.A., Cardiology and Vascular Medicine, Pusat Jantung Nasional Harapan Kita, Jakarta, Indonesia, Cardiology and Vascular Medicine, University of Indonesia Faculty of Medicine, Jakarta, Indonesia; Trivedi, P., Boehringer Ingelheim Singapore Pte Ltd, Singapore, Singapore; Zhai, D., Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, United States
Purpose Dabigatran is a direct thrombin inhibitor approved for stroke prophylaxis in patients with non-valvular atrial fibrillation (NVAF). Real-world data about patient preference, satisfaction and convenience in patients in Asia are not available. The study aimed to explore the perception of patients with newly diagnosed NVAF regarding dabigatran versus vitamin K antagonists (VKAs), when used for stroke prevention. Patients and methods This was a multinational, multicentre, non-interventional study involving 49 sites across 5 countries in South East Asia and South Korea where 934 patients newly diagnosed with NVAF were initiated on either dabigatran (N=591) or VKA (N=343). Data were collected at baseline and over two follow-up visits across 6 months. Treatment satisfaction and patient convenience were evaluated using the Perception on Anticoagulant Treatment Questionnaire-2 (PACT-Q2). Results The mean age of the patients was 65.9±10.4 years, and 64.2% were male. Mean CHA 2 DS 2-VASc score was 2.4±1.5, and mean HAS-BLED score was 1.2±0.9. At baseline, patients initiated on dabigatran had higher stroke risk, bleeding risk, creatinine clearance and proportion of patients with concomitant illnesses compared with patients initiated on VKAs. Treatment convenience was perceived to be significantly better with dabigatran versus VKAs at visits 2 and 3 (p=0.0423 and 0.0287, respectively). Treatment satisfaction was significantly better with dabigatran compared with VKAs at visit 3 (p=0.0300). Conclusion In this study, dabigatran is associated with better patient perception in terms of treatment convenience and satisfaction compared with VKAs when used for stroke prevention in newly diagnosed NVAF patients from South East Asia and South Korea. Plain language summary Patient satisfaction with dabigatran versus VKAs in South East Asia. Patients with atrial fibrillation are at high risk of stroke and require anticoagulants for stroke prevention. Two such anticoagulants are dabigatran and VKAs. We wanted to compare the extent of satisfaction and treatment convenience among newly diagnosed patients with atrial fibrillation from the South East Asian region when they were given either dabigatran or VKAs. Consenting patients filled out a standardised questionnaire called the PACT-Q2 over three visits after they were started on either dabigatran (591 patients) or VKAs (343 patients). We found that satisfaction and convenience were significantly higher when patients received dabigatran than when they received VKAs. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Atrial fibrillation; Health care; Outcome assessment; Stroke
BMJ Publishing Group
2398595X
Article
Q1
1050
4080